< Back to previous page
Researcher
Peter Carmeliet
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Cardiac and vascular medicine
- See also: Peter Carmeliet (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Angiogenesis and Vascular Metabolism (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2012 → Today - Carmeliet Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Angiogenesis and Vascular Metabolism (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → Today - Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 1999 → 30 Sep 2005
Projects
91 - 100 of 110
- The role and therapeutical potential of oxygen sensors in amyotrophic lateral sclerosis.From1 Jan 2010 → 31 Dec 2013Funding: FWO research project (including WEAVE projects)
- Evaluation of the role of PIGF and the therapeutic potential of anti-PIGF in BCR/ABL+ leukemie.From1 Jan 2010 → 31 Dec 2012Funding: FWO research grant KAN
- In vivo evaluation of the therapeutic safety of VEGF-B lentiviral gene transfer for treatment of Amyotrophic Lateral Sclerosis.From1 Jan 2010 → 31 Dec 2010Funding: Nonprofit institution or equivalents
- Exploring novel anti-cancer strategies by targeting endothelial metabolism: an unexplored pathway.From1 Jan 2010 → 31 Dec 2013Funding: FWO research project (including WEAVE projects)
- Evaluation of the role of PIGF and the therapeutic potential of anti-PIGF in BTC/ABL+ Leukemia.From31 Dec 2009 → 31 Dec 2010Funding: Private funding of national origin - undefined
- Angiogenic factors and hypoxia signaling in bone metastasisFrom14 Oct 2009 → 14 Oct 2013Funding: BOF - Other initiatives
- Francqui-pdm Françoise BRUYERE.From1 Oct 2009 → 31 Mar 2010Funding: Foundations, funds and other with scientific goal
- Matricellular proteins: crucial regulators of cardiac remodelingFrom1 Oct 2009 → 31 Mar 2010Funding: Own budget, for example: patrimony, inscription fees, gifts
- The role and therapeutical potential of oxygen sensors in amyotrophic lateral sclerosis.From1 Oct 2009 → 3 Oct 2014Funding: FWO fellowships
- Induction of endothelial phalanx cells for therapeutic angiogenesis.From1 Oct 2009 → 1 Jan 2012Funding: FWO fellowships
Publications
1 - 10 of 587
- Fatty acid oxidation fuels natural killer cell responses against infection and cancer.(2024)
Authors: Peter Carmeliet
Pages: e231925412 - Targeting hypoxia-inducible factors: therapeutic opportunities and challenges(2024)
Authors: Peter Carmeliet
- Editorial Expression of Concern: The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system.(2024)
Authors: Peter Carmeliet
Pages: E12 - The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression (vol 23, pg 1476, 2018)(2023)
Authors: Peter Carmeliet
- Detailed protocol for a corneal thermal cauterization-based (lymph-)angiogenesis assay in mice(2023)
Authors: Anh-Co Truong, Koen Veys, Mieke Dewerchin, Peter Carmeliet
- Glucose Controls Glucagon Secretion by Regulating Fatty Acid Oxidation in Pancreatic α-Cells(2023)
Authors: Peter Carmeliet
Pages: 1446 - 1459 - Renal Endothelial Cell Metabolism in Health and Acute Kidney Injury: a window for therapeutic opportunities(2023)
Authors: Mila Borri, Peter Carmeliet, Guy Eelen, Sébastien Dumas
- VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway(2023)
Authors: Mieke Dewerchin, Peter Carmeliet
- PARTIAL MYELOID INHIBITION OF KEY GLYCOLYTIC ENZYME PFKFB3 INCREASES HEPATIC STEATOSIS AND INFLAMMATION, BUT DOES NOT AFFECT ATHEROSCLEROSIS(2023)
Authors: Peter Carmeliet
- Understanding tumour endothelial cell heterogeneity and function from single-cell omics(2023)
Authors: Peter Carmeliet
Pages: 544 - 564
Patents
1 - 10 of 10
- Carnitine palmitoyltransferase 1 inhibitors for inhibition of pathological angiogenesis (Inventor)
- Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor (Inventor)
- Inhibition of plgf to treat philadelphia chromosome positive leukemia (Inventor)
- Means and methods for treating lung hypoplasia (Inventor)
- Use of VEGF and homologues to treat neuron disorders (Inventor)
- Novel anti-PLGF antibody (Inventor)
- Anti-angiogenic therapy (Inventor)
- Responsiveness to angiogenesis inhibitors (Inventor)
- CARNITINE PALMITOYLTRANSFERASE 1 INHIBITORS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS (Inventor)
- GLUTAMINE SYNTHETASE INHIBITORS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS (Inventor)